Celgene

Celgene | August 02, 2017

US regulators have issued a green light for Celgene and Agios’ Idhifa, the first and only targeted treatment for adult patients with relapsed/refractory acute myeloid leukaemia and an isocitrate dehydrogenase-2 mutation. Acute myeloid leukaemia (AML) is a rapidly progressing cancer that forms in the bone marrow and results in an increased number of abnormal white blood cells in the bloodstream and bone marrow. The disease has many genetic mutations, which can make it difficult to treat, and pati...

Pharmaphorum Media Limited | December 03, 2018

A pair of clinical trial wins for Celgene’s luspatercept at the American Society of Haematology (ASH) meeting have set up a filing for the new drug in mid-2019. The MEDALIST trial in second-line myelodysplastic syndrome (MDS) and BELIEVE study in transfusion-dependent thalassemia (TDT) both met their primary objective of a reduced need for red blood cell transfusions compared to placebo, backing up Celgene’s assertion that luspatercept could in time become a $2 billion product....

Biospace.com | January 29, 2019

Celgene has struck another collaborative deal, even as the large pharmaceutical company is in the process of being folded into the operations of its new owner, Bristol-Myers Squibb. This morning, privately-owned drug developer Triphase Accelerator, along with its majority shareholder FACIT, announced it had struck a collaborative deal with Celgene. The companies will harness their knowledge and resources to develop a first-in-class preclinical therapeutic targeting the WDR5 protein for the treat...

Pharmaphorum Media Limited | March 01, 2019

Bristol-Myers Squibb’s (BMS) largest shareholder has come out against the company’s planned merger with Celgene, putting the future of the deal in doubt. The $74 billion deal, announced in January, would be one of the largest ever pharma mergers, and the combined company would be the world’s fourth-largest drugmaker. But now investment management firm Wellington Management Company, which owns an 8% stake in BMS, has said it cannot support the acquisition. In a statement, Wellin...